2023-04-01 12765160 2024-03-31 12765160 2023-04-01 2024-03-31 12765160 2023-03-31 12765160 2022-04-01 2023-03-31 12765160 uk-core:WithinOneYear 2023-03-31 12765160 uk-core:WithinOneYear 2024-03-31 12765160 uk-core:ShareCapital 2024-03-31 12765160 uk-core:ShareCapital 2023-03-31 12765160 uk-core:RetainedEarningsAccumulatedLosses 2024-03-31 12765160 uk-core:RetainedEarningsAccumulatedLosses 2023-03-31 12765160 uk-bus:Director1 2023-04-01 2024-03-31 12765160 uk-core:PlantMachinery 2023-04-01 2024-03-31 iso4217:GBP xbrli:pure 12765160 uk-bus:AuditExemptWithAccountantsReport 2023-04-01 2024-03-31 12765160 uk-bus:FRS102 2023-04-01 2024-03-31 12765160 uk-bus:FilletedAccounts 2023-04-01 2024-03-31 12765160 uk-bus:PrivateLimitedCompanyLtd 2023-04-01 2024-03-31
Sinha Pharma Ltd
Registered Number:12765160
For the year ended 31 March 2024
England and Wales
Unaudited Financial Statements
2
For the year ended 31 March 2024
Sinha Pharma Ltd
Contents Page
1
Statement of Financial Position
2 to 3
Notes to the Financial Statements
3
Registered Number :
12765160
As at 31 March 2024
Sinha Pharma Ltd
Statement of Financial Position
£
£
2023
2024
Notes
Fixed assets
Property, plant and equipment
218
1,065
2
218
1,065
Current assets
Trade and other receivables
1,530
5,262
3
65,034
Cash and cash equivalents
57,948
63,210
66,564
Trade and other payables: amounts falling due within one
year
(44,207)
(14,793)
4
22,357
48,417
Net current assets
Total assets less current liabilities
48,635
23,422
48,635
Net assets
23,422
Capital and reserves
Called up share capital
1
1
Retained earnings
48,634
23,421
48,635
23,422
Shareholders' funds
For the year ended 31 March 2024 the company was entitled to exemption from audit under Section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2024 in accordance with Section 476 of the Companies Act 2006
The director acknowledges his responsibilities for:a) ensuring that the company keeps proper accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the
end of each financial year and of its profit or loss for each financial year in accordance with the requirements
of Section 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006
relating to financial statements, so far as applicable to the company.
In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.
The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
S. Sinha Director
These financial statements were approved and authorised for issue by the Board on 21 July 2024 and were signed by:
The notes form part of these financial statements
1 of 3
4
For the year ended 31 March 2024
Sinha Pharma Ltd
Notes to the Financial Statements
Statutory Information
Sinha Pharma Ltd is a private limited company, limited by shares, domiciled in England and Wales, registration
number 12765160.
Registered address:
23 Beech Court
Ponteland
Newcastle upon Tyne
NE20 9NE
The presentation currency is £ sterling.
1. Accounting policies
Basis of preparing the financial statements
These financial statements have been prepared in accordance with the provisions of Section 1A of Financial
Reporting Standard 102 ''The Financial Reporting Standard applicable in the UK and Republic of Ireland'' and
the Companies Act 2006. The financial statements have been prepared under the historical costs convention as
modified by the revaluation of certain assets.
Going Concern
The financial statements have been prepared on a going concern basis as the directors believe that no material
uncertainties exist. The directors have considered the level of funds held and the expected level of income and
expenditure for 12 months from authorising these financial statements and have concluded that the company is
able to continue as a going concern.
Property, plant and equipment
Property, plant and equipment, other than freehold land, are stated at cost or valuation less depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following basis:
Plant and Machinery
50% Straight line
2 of 3
5
For the year ended 31 March 2024
Sinha Pharma Ltd
Notes to the Financial Statements Continued
2. Property, plant and equipment
Plant and
Machinery
£
Cost or
valuation
At 01 April 2023
3,086
436
Additions
At 31 March 2024
3,522
Provision for depreciation and impairment
At 01 April 2023
2,021
Charge for year
1,283
At 31 March 2024
3,304
At 31 March 2024
Net book value
218
At 31 March 2023
1,065
3. Trade and other receivables
2023
2024
£
£
Trade debtors
5,262
1,530
4. Trade and other payables: amounts falling due within one year
2023
2024
£
£
Taxation and social security
5,898
5,907
Directors' loan accounts
7,105
36,117
Other creditors
1,790
2,183
14,793
44,207
5. Average number of persons employed
During the year the average number of employees were 1 (2023 : 1)
3 of 3